Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors

NCT02163759 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02163759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02163759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
November 4, 2014
Completion date
March 19, 2020
Enrollment
358 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis